Taken together, these preclinical results unveil complex signaling pathways between the Trp catabolic enzymes IDO1and TDO2, the Kyn and the ligand-operated transcription factor AhR, which is dysregulated by cancer cells to highjack antitumor immunity and develop resistance to anticancer therapies, particularly in the immunotherapy era. Here, TDO2 is linked to cancer.